Lily Soto

Dr. Lily Soto


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 July 2026 in Travel Medicine and Infectious Disease
Verified
Journal Article
Open access
Alfonso J. Rodriguez-MoralesAlfonso J. Rodriguez-Morales
Alfonso J. Rodriguez-Morales
IRIvan Arturo Rodríguez-Sabogal
Ivan Arturo Rodríguez-Sabogal
ASAdriana Sucari
Adriana Sucari
WMWendy Moncada
Wendy Moncada
LHLili Vanessa Hernández-Serrano
Lili Vanessa Hernández-Serrano
MMMario Masana
Mario Masana

7 August 2022 in HIV Medicine
Verified
Journal Article
Closed access
YGYoel D. García
Yoel D. García
FUFrancisco A. Ureña
Francisco A. Ureña
FCFhabián S. Carrión‐Nessi
Fhabián S. Carrión‐Nessi
SDSol Y. Díaz
Sol Y. Díaz
AÁAtahualpa A. Ávila
Atahualpa A. Ávila
DFDavid A. Forero-Peña
David A. Forero-Peña

Verified
Journal Article
Open access
PDF file
Alfonso J. Rodriguez-MoralesAlfonso J. Rodriguez-Morales
Alfonso J. Rodriguez-Morales
KAKatherine Acevedo-Jimenez
Katherine Acevedo-Jimenez
MGMaría Eugenia Guevara
María Eugenia Guevara
ACAlicia Chang-Cojulun
Alicia Chang-Cojulun
JCJosé Brea-Del Castillo
José Brea-Del Castillo
JSJosé Antonio Suárez
José Antonio Suárez
Yellow fever remains a major public health threat in endemic and re-emerging regions of Africa and South America, with recent outbreaks highlighting persistent gaps in prevention and surveillance. Pregnant women represent a particularly vulnerable population, yet the epidemiology, clinical impact, and preventive strategies for yellow fever in pregnancy are insufficiently characterized. Physiological and immunological changes during gestation may influence host responses to infection; however, current evidence does not demonstrate increased susceptibility to or severity of yellow fever during pregnancy. Adverse materno-fetal outcomes, including miscarriage, stillbirth, preterm birth, and, in rare cases, perinatal transmission, have been reported but remain poorly characterized. Diagnostic challenges, overlapping clinical presentations with other arboviral and hepatic diseases, and limited access to specialized care further complicate clinical management in many endemic settings. This perspective provides a comprehensive overview of yellow fever in pregnancy during the 2024–2026 outbreak in the Americas, including a risk-stratification framework for prevention. We summarize current evidence on epidemiology, pathophysiology, diagnosis, and supportive care, and examine prevention strategies with particular emphasis on vaccination. Accumulated observational evidence and substantial real-world experience have not demonstrated an increased risk of serious adverse events and generally support the effectiveness of yellow fever vaccination during pregnancy when administered with appropriate clinical judgment. In high-risk settings, the benefits of maternal immunization clearly outweigh theoretical concerns, supporting a flexible, risk-based approach, despite relatively limited evidence. We also discuss national and international policies, post-pregnancy booster recommendations, and the importance of integrating vaccination assessment into antenatal care. Finally, we highlight critical knowledge gaps and research priorities, including the need for prospective registries and strengthened pharmacovigilance. Coordinated clinical and public health strategies are essential to protect maternal and neonatal health and to reduce the burden of yellow fever in endemic and re-emerging settings.

4 August 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
LSLily Soto
Lily Soto
HFHiginio Fernández-Sánchez
Higinio Fernández-Sánchez
Alfonso J. Rodriguez-MoralesAlfonso J. Rodriguez-Morales
Alfonso J. Rodriguez-Morales
Background: Hematologic abnormalities are common in people living with human immunodeficiency virus (HIV) and may reflect underlying infectious, neoplastic, or inflammatory processes involving the bone marrow. In patients with advanced HIV infection, these abnormalities frequently prompt bone marrow evaluation, particularly in the presence of fever of unknown origin or unexplained cytopenias. However, data describing the etiologic spectrum of bone marrow disease in resource-limited settings remain limited. In Latin America, where approximately 2.5 million people are living with HIV [1], late diagnosis and limited access to diagnostic infrastructure remain significant barriers. Yet, contemporary data on the etiologic spectrum of bone marrow involvement in this region are scarce. Aim: To describe the etiologic distribution, histopathological findings, and clinical characteristics of infiltrative bone marrow disease among adults living with HIV who underwent bone marrow evaluation at a tertiary referral center in Venezuela. Methods: We conducted a descriptive cross-sectional study with retrospective and prospective case inclusion among adults with confirmed HIV infection who underwent bone marrow aspiration and/or biopsy for suspected infiltrative disease between January 2019 and April 2024. Clinical, laboratory, histopathological, microbiological, and molecular data were collected. Descriptive analyses and exploratory comparisons were performed. Continuous variables were compared using the Mann-Whitney U test, and categorical variables were analyzed using chi-square or Fisher's exact test, as appropriate. Results: A total of 42 patients were included; 60% were male, and the median age was 39 years (IQR: 31.75–50.0). At presentation, 67% were newly diagnosed with HIV, and 79% were antiretroviral therapy naïve. Severe immunosuppression was common, with a median CD4+ T-cell count of 98.5 cells/mm³. Bone marrow histopathology most frequently demonstrated granulomatous inflammation and hypocellularity (each 38%). Infectious etiologies were identified in 85% of cases, with Histoplasma capsulatum (49%) and Mycobacterium tuberculosis (39%) being the most common pathogens among those tested. Malignancies accounted for 16% of evaluable biopsies. Denominators varied across analyses because not all patients had complete microbiological or histopathological data available. This study provides one of the few contemporary datasets on bone marrow pathology in HIV in Latin America. Conclusions: In this biopsy-selected cohort of adults with advanced HIV infection, infectious etiologies, particularly histoplasmosis and tuberculosis, were the predominant causes of infiltrative bone marrow disease. Bone marrow evaluation provided clinically relevant diagnostic information in patients with fevers of unknown origin and cytopenias when noninvasive investigations were inconclusive. These findings highlight the need for earlier HIV diagnosis, timely initiation of antiretroviral therapy, and improved access to microbiological and molecular diagnostic tools in resource-limited settings. Evidence contributes to the limited body of evidence on bone marrow pathology in people living with HIV in Latin America. It may inform diagnostic and public health strategies in similar resource-limited settings.

6 March 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
Alfonso J. Rodriguez-MoralesAlfonso J. Rodriguez-Morales
Alfonso J. Rodriguez-Morales
KAKatherine Acevedo-Jimenez
Katherine Acevedo-Jimenez
MGMaría Eugenia Guevara
María Eugenia Guevara
ACAlicia Chang-Cojulun
Alicia Chang-Cojulun
JCJosé Brea-Del Castillo
José Brea-Del Castillo
JSJosé Antonio Suárez
José Antonio Suárez
Yellow fever remains a major public health threat in endemic and re-emerging regions of Africa and South America, with recent outbreaks highlighting persistent gaps in prevention and surveillance. Pregnant women represent a particularly vulnerable population, yet the epidemiology, clinical impact, and preventive strategies for yellow fever in pregnancy are insufficiently characterized. Physiological and immunological changes during gestation may increase susceptibility to severe disease and contribute to adverse maternal and fetal outcomes, including miscarriage, stillbirth, preterm birth, and, in rare cases, perinatal transmission. Diagnostic challenges, overlapping clinical presentations with other arboviral and hepatic diseases, and limited access to specialized care further complicate clinical management in many endemic settings. This perspective provides a comprehensive overview of yellow fever in pregnancy during the 2024–2026 outbreak in the Americas, including a risk-stratification framework for prevention. We summarize current evidence on epidemiology, pathophysiology, diagnosis, and supportive care, and examine prevention strategies with particular emphasis on vaccination. Accumulated observational evidence and substantial real-world experience have not demonstrated an increased risk of serious adverse events and generally support the effectiveness of yellow fever vaccination during pregnancy when administered with appropriate clinical judgment. In high-risk settings, the benefits of maternal immunization clearly outweigh theoretical concerns, supporting a flexible, risk-based approach, despite relatively limited evidence. We also discuss national and international policies, post-pregnancy booster recommendations, and the importance of integrating vaccination assessment into antenatal care. Finally, we highlight critical knowledge gaps and research priorities, including the need for prospective registries and strengthened pharmacovigilance. Coordinated clinical and public health strategies are essential to protect maternal and neonatal health and to reduce the burden of yellow fever in endemic and re-emerging settings.

6 May 2026 in Microorganisms
Verified
Journal Article
Open access
PDF file
JBJulie Andreina Beltran
Julie Andreina Beltran
YGYoneira Fabiola Sulbaran Garcia
Yoneira Fabiola Sulbaran Garcia
LSLily Soto
Lily Soto
CPCarlos Pérez
Carlos Pérez
MCMario Comegna
Mario Comegna
RJRossana C Jaspe
Rossana C Jaspe
Hepatitis E virus (HEV) is an emerging zoonotic pathogen of increasing concern in developed regions and represents a major cause of acute viral hepatitis worldwide, primarily transmitted via the fecal–oral route. Although most infections are self-limiting, immunocompromised individuals, such as people living with human immunodeficiency virus (PLWH) and pregnant women, are at risk of severe outcomes, including chronic infection and fatal liver failure, respectively. This study was aimed at evaluating the prevalence and genetic diversity of HEV in PLWH and relevant ecological niches (swine and wastewater) in Venezuela. A total of 417 serum samples from PLWH, 85 wastewater samples, and 67 swine fecal samples were tested for serological or molecular HEV markers. The seroprevalence of anti-HEV antibodies among PLWH was 0.2% for IgM and 5.5% for IgG. HEV RNA was not detected in samples from PLWH or wastewater; however, a 1.5% prevalence of active infection was identified in swine. Phylogenetic analysis of a complete HEV genome revealed an unassignable subtype within genotype 3, tentatively designated as 3p. To the best of our knowledge, this study provides the first molecular characterization and report on HEV frequency in PLWH, wastewater, and swine in Venezuela.